Cholesterol epoxide hydrolase and cancer

Current Opinion in Pharmacology

Volumn 12, Issue 6, 2012, Pages 696-703

  Silvente Poirot, Sandrine ^a   Poirot, Marc ^a  

^a CANCER RESEARCH CENTER OF TOULOUSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3BETA (2 DIETHYLAMINOETHOXY)ANDROST 5 EN 17 ONE; 3BETA HYDROXYSTEROL DELTA7 REDUCTASE; 3BETA HYDROXYSTEROL DELTA8 DELTA7 ISOMERASE; 7 OXOCHOLESTEROL; AFIMOXIFENE; AMIODARONE; ANTINEOPLASTIC AGENT; ARACHIDONIC ACID; CHOLESTANETRIOL; CHOLESTEROL DERIVATIVE; CHOLESTEROL EPOXIDE HYDROLASE; CHOLESTEROL EPOXIDE HYDROLASE INHIBITOR; CLOMIFENE; DOCOSAHEXAENOIC ACID; EPOXIDE; HALOPERIDOL; HYDROLASE; HYDROLASE INHIBITOR; ISOMERASE; LINOLENIC ACID; N CYCLOHEXYL N ETHYL 3 (3 CHLORO 4 CYCLOHEXYLPHENYL) 2 PROPENYLAMINE; NUCLEOPHILE; OLEIC ACID; OXIDOREDUCTASE; RALOXIFENE; TAMOXIFEN; TESMILIFENE; TRIFLUOPERAZINE; TRIPARANOL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; BIOACCUMULATION; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CELL DEATH; CELL DIFFERENTIATION; CHEMOPROPHYLAXIS; CHOLESTEROL SYNTHESIS; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME SUBSTRATE; FETUS DEVELOPMENT; FETUS GROWTH; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; TISSUE DISTRIBUTION; TUMOR CELL;

EID: 84870562706     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2012.07.007     Document Type: Review

References (53)

1. J.W. Newman, C. Morisseau, and B.D. Hammock Epoxide hydrolases: their roles and interactions with lipid metabolism Prog Lipid Res 44 2005 1 51
2. A. Sevanian, and L.L. McLeod Catalytic properties and inhibition of hepatic cholesterol-epoxide hydrolase J Biol Chem 261 1986 54 59
3. J.T. Chan, and H.S. Black Skin carcinogenesis: cholesterol-5alpha, 6alpha-epoxide hydrase activity in mouse skin irradiated with ultraviolet light Science 186 1974 1216 1217
4. Poirot M, Silvente-Poirot S: Cholesterol-5,6-epoxides: chemistry, biochemistry, metabolic fate and cancer. Biochimie, in press, http://dx.doi.org/10.1016/j.biochi.2012.05.006.
5. M.R. Paillasse, N. Saffon, H. Gornitzka, S. Silvente-Poirot, M. Poirot, and P. de Medina Surprising unreactivity of cholesterol-5,6-epoxides towards nucleophiles J Lipid Res 53 2012 718 725
6. K. el-Bayoumy, B.Y. Ji, P. Upadhyaya, Y.H. Chae, C. Kurtzke, A. Rivenson, B.S. Reddy, S. Amin, and S.S. Hecht Lack of tumorigenicity of cholesterol epoxides and estrone-3,4-quinone in the rat mammary gland Cancer Res 56 1996 1970 1973
7. A. Astrom, M. Eriksson, L.C. Eriksson, W. Birberg, A. Pilotti, and J.W. DePierre Subcellular and organ distribution of cholesterol epoxide hydrolase in the rat Biochim Biophys Acta 882 1986 359 366
8. P. de Medina, M.R. Paillasse, G. Segala, M. Poirot, and S. Silvente-Poirot Identification and pharmacological characterization of cholesterol-5,6-epoxide hydrolase as a target for tamoxifen and AEBS ligands Proc Natl Acad Sci U S A 107 2010 13520 13525
9. B. Kedjouar, P. de Medina, M. Oulad-Abdelghani, B. Payre, S. Silvente-Poirot, G. Favre, J.C. Faye, and M. Poirot Molecular characterization of the microsomal tamoxifen binding site J Biol Chem 279 2004 34048 34061
10. F. Mesange, M. Sebbar, B. Kedjouar, J. Capdevielle, J.C. Guillemot, P. Ferrara, F. Bayard, F. Delarue, J.C. Faye, and M. Poirot Microsomal epoxide hydrolase of rat liver is a subunit of the anti-oestrogen-binding site Biochem J 334 Pt 1 1998 107 112
11. F. Muller, M. Arand, H. Frank, A. Seidel, W. Hinz, L. Winkler, K. Hanel, E. Blee, J.K. Beetham, B.D. Hammock, and F. Oesch Visualization of a covalent intermediate between microsomal epoxide hydrolase, but not cholesterol epoxide hydrolase, and their substrates Eur J Biochem 245 1997 490 496
12. J.Z. Haeggstrom Leukotriene A4 hydrolase/aminopeptidase, the gatekeeper of chemotactic leukotriene B4 biosynthesis J Biol Chem 279 2004 50639 50642
13. J.W. Newman, C. Morisseau, T.R. Harris, and B.D. Hammock The soluble epoxide hydrolase encoded by EPXH2 is a bifunctional enzyme with novel lipid phosphate phosphatase activity Proc Natl Acad Sci U S A 100 2003 1558 1563
14. F.D. Porter, and G.E. Herman Malformation syndromes caused by disorders of cholesterol synthesis J Lipid Res 52 2011 6 34
15. V.C. Jordan SERMs: meeting the promise of multifunctional medicines J Natl Cancer Inst 99 2007 350 356
16. P. Bougnoux, N. Hajjaji, and C. Couet The lipidome as a composite biomarker of the modifiable part of the risk of breast cancer Prostaglandins Leukot Essent Fatty Acids 79 2008 93 96
17. B. Payre, P. de Medina, N. Boubekeur, L. Mhamdi, J. Bertrand-Michel, F. Terce, I. Fourquaux, D. Goudouneche, M. Record, M. Poirot, and S. Silvente-Poirot Microsomal antiestrogen-binding site ligands induce growth control and differentiation of human breast cancer cells through the modulation of cholesterol metabolism Mol Cancer Ther 7 2008 3707 3718
18. P. de Medina, B. Payre, N. Boubekeur, J. Bertrand-Michel, F. Terce, S. Silvente-Poirot, and M. Poirot Ligands of the antiestrogen-binding site induce active cell death and autophagy in human breast cancer cells through the modulation of cholesterol metabolism Cell Death Differ 16 2009 1372 1384
19. P. de Medina, S. Silvente-Poirot, and M. Poirot Tamoxifen and AEBS ligands induced apoptosis and autophagy in breast cancer cells through the stimulation of sterol accumulation Autophagy 5 2009 1066 1067
20. L. Reyno, L. Seymour, D. Tu, S. Dent, K. Gelmon, B. Walley, A. Pluzanska, V. Gorbunova, A. Garin, J. Jassem, and T. Pienkowski Phase III study of N, N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19 J Clin Oncol 22 2004 269 276
21. T. Deng, J.C. Liu, K.I. Pritchard, A. Eisen, and E. Zacksenhaus Preferential killing of breast tumor initiating cells by N,N-diethyl-2-[4- (phenylmethyl)phenoxy]ethanamine/tesmilifene Clin Cancer Res 15 2009 119 130
22. A. Ao, B.J. Morrison, H. Wang, J.A. Lopez, B.A. Reynolds, and J. Lu Response of estrogen receptor-positive breast cancer tumorspheres to antiestrogen treatments PLoS One 6 2011 e18810
23. T. Hayon, A. Dvilansky, L. Oriev, and I. Nathan Non-steroidal antiestrogens induce apoptosis in HL60 and MOLT3 leukemic cells; involvement of reactive oxygen radicals and protein kinase C Anticancer Res 19 1999 2089 2093
24. G. Yom-Tov, I. Nathan, O. Shpilberg, A. Polliack, and I. Levi Clomiphene as a novel modality for the treatment of acute myeloid leukemia: a pilot phase II study Leuk Res 36 2012 42 45
25. J.B. Massey, and H.J. Pownall Structures of biologically active oxysterols determine their differential effects on phospholipid membranes Biochemistry 45 2006 10747 10758
26. C. Ishimaru, Y. Yonezawa, I. Kuriyama, M. Nishida, H. Yoshida, and Y. Mizushina Inhibitory effects of cholesterol derivatives on DNA polymerase and topoisomerase activities, and human cancer cell growth Lipids 43 2008 373 382
27. S.B. Joseph, A. Castrillo, B.A. Laffitte, D.J. Mangelsdorf, and P. Tontonoz Reciprocal regulation of inflammation and lipid metabolism by liver X receptors Nat Med 9 2003 213 219
28. L.L. Vedin, S.A. Lewandowski, P. Parini, J.A. Gustafsson, and K.R. Steffensen The oxysterol receptor LXR inhibits proliferation of human breast cancer cells Carcinogenesis 30 2009 575 579
29. V. Russo Metabolism, LXR/LXR ligands, and tumor immune escape J Leukoc Biol 90 2011 673 679
30. T.J. Berrodin, Q. Shen, E.M. Quinet, M.R. Yudt, L.P. Freedman, and S. Nagpal Identification of 5{alpha},6{alpha}-epoxycholesterol as a novel modulator of liver x receptor activity Mol Pharmacol 78 2010 1046 1058
31. C. Song, R.A. Hiipakka, and S. Liao Auto-oxidized cholesterol sulfates are antagonistic ligands of liver X receptors: implications for the development and treatment of atherosclerosis Steroids 66 2001 473 479
32. S.P. Pitroda, N.N. Khodarev, M.A. Beckett, D.W. Kufe, and R.R. Weichselbaum MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment Proc Natl Acad Sci U S A 106 2009 5837 5841
33. B.S. Reddy, and E.L. Wynder Metabolic epidemiology of colon cancer. Fecal bile acids and neutral sterols in colon cancer patients and patients with adenomatous polyps Cancer 39 1977 2533 2539
34. B.S. Reddy, C.W. Martin, and E.L. Wynder Fecal bile acids and cholesterol metabolites of patients with ulcerative colitis, a high-risk group for development of colon cancer Cancer Res 37 1977 1697 1701
35. Y.W. Cheng, J.J. Kang, Y.L. Shih, Y.L. Lo, and C.F. Wang Cholesterol-3-beta, 5-alpha, 6-beta-triol induced genotoxicity through reactive oxygen species formation Food Chem Toxicol 43 2005 617 622
36. L. Aringer, and P. Eneroth Formation and metabolism in vitro of 5,6-epoxides of cholesterol and beta-sitosterol J Lipid Res 15 1974 389 398
37. de Medina P, Silvente-Poirot S, Poirot M: Methods for determining the oncogenic condition of cell, use thereof, and methods for treating cancer. Word Patent, 2010/149941; 2010
38. D. Raghavan, L.J. Brandes, K. Klapp, T. Snyder, E. Styles, D. Tsao-Wei, G. Lieskovsky, D.I. Quinn, and E.W. Ramsey Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: high subjective and objective response in patients with symptomatic metastases J Urol 174 2005 1808 1813 (discussion 1813)
39. M. Vincent Tesmilifene may enhance breast cancer chemotherapy by killing a clone of aggressive, multi-drug resistant cells through its action on the p-glycoprotein pump Med Hypotheses 66 2006 715 731
40. P. de Medina, M.R. Paillasse, B. Payre, S. Silvente-Poirot, and M. Poirot Synthesis of new alkylaminooxysterols with potent cell differentiating activities: identification of leads for the treatment of cancer and neurodegenerative diseases J Med Chem 52 2009 7765 7777
41. E. Prommer Role of haloperidol in palliative medicine: an update Am J Hosp Palliat Care 29 2012 295 301
42. B. Bourrie, E. Bribes, J.M. Derocq, H. Vidal, and P. Casellas Sigma receptor ligands: applications in inflammation and oncology Curr Opin Investig Drugs 5 2004 1158 1163
43. L.O. Marques, M.S. Lima, and B.G. Soares Trifluoperazine for schizophrenia Cochrane Database Syst Rev 2004 CD003545
44. H. Van Herendael, and P. Dorian Amiodarone for the treatment and prevention of ventricular fibrillation and ventricular tachycardia Vasc Health Risk Manage 6 2010 465 472
45. C.Y. Wang, Q. Wei, I. Han, S. Sato, R. Ghanbari-Azarnier, H. Whetstone, R. Poon, J. Hu, F. Zheng, P. Zhang, and W. Wang Hedgehog and Notch signaling regulate self-renewal of undifferentiated pleomorphic sarcomas Cancer Res 72 2012 1013 1022
46. J.G. Newland, and S.M. Abdel-Rahman Update on terbinafine with a focus on dermatophytoses Clin Cosmet Investig Dermatol 2 2009 49 63
47. R.J. Cenedella Cholesterol synthesis inhibitor U18666A and the role of sterol metabolism and trafficking in numerous pathophysiological processes Lipids 44 2009 477 487
48. D. Torocsik, A. Szanto, and L. Nagy Oxysterol signaling links cholesterol metabolism and inflammation via the liver X receptor in macrophages Mol Aspects Med 30 2009 134 152
49. M.M. Mahfouz, T.L. Smith, Q. Zhou, and F.A. Kummerow Cholestane-3 beta, 5 alpha, 6 beta-triol stimulates phospholipid synthesis and CTP-phosphocholine cytidyltransferase in cultured LLC-PK cells Int J Biochem Cell Biol 28 1996 739 750
50. J.A. Menendez, A. Papadimitropoulou, L. Vellon, and R. Lupu A genomic explanation connecting "Mediterranean diet", olive oil and cancer: oleic acid, the main monounsaturated fatty acid of olive oil, induces formation of inhibitory "PEA3 transcription factor-PEA3 DNA binding site" complexes at the Her-2/neu (erbB-2) oncogene promoter in breast, ovarian and stomach cancer cells Eur J Cancer 42 2006 2425 2432
51. J.A. Menendez, A. Vazquez-Martin, S. Ropero, R. Colomer, and R. Lupu HER2 (erbB-2)-targeted effects of the omega-3 polyunsaturated fatty acid, alpha-linolenic acid (ALA; 18:3n-3), in breast cancer cells: the "fat features" of the "Mediterranean diet" as an "anti-HER2 cocktail" Clin Transl Oncol 8 2006 812 820
52. V. Wijendran, and K.C. Hayes Dietary n-6 and n-3 fatty acid balance and cardiovascular health Annu Rev Nutr 24 2004 597 615
53. P. Bougnoux, N. Hajjaji, K. Maheo, C. Couet, and S. Chevalier Fatty acids and breast cancer: sensitization to treatments and prevention of metastatic re-growth Prog Lipid Res 49 2010 76 86